瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

已收盘 11-10 16:08:36

44.540

+1.160

+2.67%

最高45.960	最低43.360	成交量15.05万
今开45.960	昨收43.380	日振幅5.99%
总市值75.27亿	流通市值75.27亿	总股本1.69亿
成交额671.83万	换手率0.09%	流通股本1.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":44.54,"timestamp":1794298116010,"preClose":43.38,"halted":0,"volume":150459,"delay":0,"changeRate":0.026740433379437448,"floatShares":169000000,"shares":169000000,"eps":-2.100221,"marketStatus":"已收盘","change":1.16,"latestTime":"11-10 16:08:36","open":45.96,"high":45.96,"low":43.36,"amount":6718263,"amplitude":0.059935,"askPrice":44.54,"askSize":800,"bidPrice":44.18,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794360600000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":43.38,"openAndCloseTimeList":[[1794274200000,1794283200000],[1794286800000,1794297600000]],"volumeRatio":0.563916,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2682359915","title":"港股异动 | 瑞博生物-B(06938)早盘涨近6% 已在欧盟提交双靶点siRNA药物SR122的I期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2682359915","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682359915?lang=zh_cn&edition=full","pubTime":"2026-11-10 10:13","pubTimestamp":1794276821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B早盘涨近6%，截至发稿，涨3.18%，报44.76港元，成交额336.18万港元。消息面上，11月10日，瑞博生物-B发布公告，本公司已在欧盟提交本公司自主研发产品双靶点siRNA药物SR122的I期临床试验申请。本次I期临床试验为一项随机、安慰剂对照研究，旨在评估健康受试者皮下注射 SR122的安全性、耐受性、药代动力学及药效学。该研究将首次在人体中对双靶点药物SR122进行临床评估，并将产生关键数据以支持其进一步开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK4585","IBBJ","FESXmain","BK4588","MDTX","KCAI","PSYK","FSXEmain","IBBQ","BMED","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682373358","title":"瑞博生物-B(06938.HK)提交双靶点药物SR122注射液用于治疗混合型血脂异常及重度高甘油三酯血症的I期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2682373358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682373358?lang=zh_cn&edition=full","pubTime":"2026-11-10 07:52","pubTimestamp":1794268375,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682358378","title":"瑞博生物-B(06938)提交双靶点药物SR122注射液用于治疗混合型血脂异常及重度高甘油三酯血症的I期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2682358378","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682358378?lang=zh_cn&edition=full","pubTime":"2026-11-10 07:52","pubTimestamp":1794268375,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司已在欧盟提交本公司自主研发产品双靶点siRNA药物SR122的I期临床试验申请。尽管目前已有降脂疗法，但混合型血脂异常患者往往仍面临显著的残余心血管风险，而严重高甘油三酯血症患者罹患急性胰腺炎的风险亦会增加。该研究将首次在人体中对双靶点药物SR122进行临床评估，并将产生关键数据以支持其进一步开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IBBJ","PSYK","MDTX","IBBQ","BMED","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150940717","title":"瑞博生物-B（06938）向欧盟递交双靶点siRNA药物SR122一期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1150940717","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150940717?lang=zh_cn&edition=full","pubTime":"2026-11-10 07:46","pubTimestamp":1794267964,"startTime":"0","endTime":"0","summary":"2026年11月10日，苏州瑞博生物技术股份有限公司发布自愿公告称，已在欧盟递交其自主研发的双靶点siRNA药物SR122注射液用于治疗血脂异常的I期临床试验申请。\\n\\n据公告，SR122同时靶向ApoC3与PCSK9两个已获临床验证的靶点，在干预富含甘油三酯的脂蛋白及低密度脂蛋白胆固醇方面具有互补作用。除SR122外，瑞博生物-B目前正在欧洲及中国推进核心降脂产品RBD5044的II期临床研究。这将是SR122首次进入人体试验，所得数据将用于后续开发决策。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682750821","title":"瑞博生物-B于11月6日斥资153.28万港元回购3.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2682750821","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682750821?lang=zh_cn&edition=full","pubTime":"2026-11-09 07:31","pubTimestamp":1794180660,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端瑞博生物-B（06938）发布公告，于2026年11月6日斥资153.28万港元回购3.58万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-11-09/doc-iniyauwa6430664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132127957","title":"瑞博生物-B：11月6日回购35,800股，耗资约153.28万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132127957","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132127957?lang=zh_cn&edition=full","pubTime":"2026-11-06 19:12","pubTimestamp":1793963528,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年11月6日公告，进行了一次股份回购交易。公司在香港联交所场内回购35,800股普通股，占当日回购前已发行股本约0.0211%，每股回购价格介乎每股42.32港元至43港元，总涉资约153.28万港元。本次回购完成后，公司已发行股本总数增减后为170,554,910股，库藏股数量达到1,283,400股。公司回购授权决议于2026年6月5日获通过，可回购股份总数为17,055,491股。截至目前，公司已合计回购股份1,283,400股，占授权通过日已发行股本约0.7525%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：11月6日回购35,800股，耗资约153.28万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681850160","title":"瑞博生物-B(06938)11月6日斥资153.28万港元回购3.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681850160","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681850160?lang=zh_cn&edition=full","pubTime":"2026-11-06 19:08","pubTimestamp":1793963296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年11月6日斥资153.28万港元回购3.58万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128236420","title":"瑞博生物-B更新10月股份变动月报表，回购185,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1128236420","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128236420?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:46","pubTimestamp":1793872013,"startTime":"0","endTime":"0","summary":"2026年11月5日，瑞博生物-B发布2026年10月股份变动月报表。公司本月法定注册股本维持人民币170,554,910元不变，股本总额仍为170,554,910股。截至10月31日，公司已发行股份为169,397,310股，较上月底减少185,600股；库存股份增至1,157,600股。公告显示，公司于本月完成多次回购，合计回购185,600股H股，并将其作为库存股份持有，回购价格区间为每股港币42.1719元至52.25元，交易日期分别为2026年10月21日、22日、23日、27日及29日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162035888","title":"瑞博生物-B：11月3日回购9万股，耗资约367.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162035888","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162035888?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:25","pubTimestamp":1793708754,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年11月3日公告，公司当日在香港联交所场内回购H股9万股，占回购前已发行股份约0.0531%。每股回购价介乎40.30港元至41.20港元，涉资约367.68万港元。本次回购完成后，公司于2026年11月3日的已发行股份数为169,307,310股，库藏股数增至1,247,600股，合计股本仍为170,554,910股。公告显示，购回授权于2026年6月5日获得通过，可回购股份总数为17,055,491股。公司确认本次回购符合香港联合交易所有限公司证券上市规则及其他适用法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B：11月3日回购9万股，耗资约367.68万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680726664","title":"瑞博生物-B(06938)11月3日斥资367.68万港元回购9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680726664","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680726664?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:23","pubTimestamp":1793708595,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年11月3日斥资367.68万港元回购9万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181944884","title":"瑞博生物-B(06938)10月29日回购6万股，涉资约259.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181944884","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181944884?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:01","pubTimestamp":1793271695,"startTime":"0","endTime":"0","summary":"瑞博生物-B(06938)于2026年10月29日在香港联交所发布翌日披露报表，公告显示公司当日回购股份6万股，占回购前公司已发行股本约0.0354%，每股回购价介乎43.06港元至43.30港元，总金额约259.68万港元。\n回购完成后，公司已发行股份总数为169,397,310股，库藏股数量增至1,157,600股。上述回购依据公司于2026年6月5日通过的购回授权进行。公司并确认本次回购符合香港联交所证券上市规则及相关法律法规。\n本公告由公司联席公司秘书张甦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B(06938)10月29日回购6万股，涉资约259.68万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679040887","title":"瑞博生物-B(06938)10月29日斥资259.68万港元回购6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679040887","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679040887?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:57","pubTimestamp":1793271442,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年10月29日斥资259.68万港元回购6万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181888808","title":"瑞博生物-B于10月27日回购5万股股份，耗资约210.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181888808","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181888808?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:42","pubTimestamp":1793097760,"startTime":"0","endTime":"0","summary":"瑞博生物-B于2026年10月27日发布公告，宣布在香港联合交易所场内回购5万股普通股。此次回购占该公司此前已发行股本的约0.0295%，每股回购价格在每股41.70港元至42.60港元之间，合计耗资约210.86万港元。公告显示，本次回购完成后，公司已发行股本变更为169,457,310股，库藏股数量达1,097,600股，总股本维持在170,554,910股。公司表示，回购授权于2026年6月5日获得股东大会批准，可回购股份总数为17,055,491股，目前已累计回购1,097,600股，占授权数量的0.6435%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B于10月27日回购5万股股份，耗资约210.86万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678439173","title":"瑞博生物-B(06938.HK)10月27日斥资210.86万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678439173","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678439173?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:37","pubTimestamp":1793097470,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677926729","title":"瑞博生物-B(06938.HK)10月23日斥资182.1万港元回购3.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677926729","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677926729?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:10","pubTimestamp":1792753814,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191637848","title":"瑞博生物-B回购3.82万股，耗资约182.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191637848","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191637848?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:06","pubTimestamp":1792753576,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年10月23日发布公告，报告当日在香港联交所场内回购公司H股3.82万股，约占回购前已发行股份总数的0.0225%。本次回购价格区间为每股46.72港元至48港元，合计动用资金约182.11万港元。公告显示，本次回购完成后，公司已发行股份总数维持在1.71亿股，其中不含库藏股的已发行股份总数为1.70亿股，库藏股数量增至104.76万股。公司亦提示，依据相关规定，在本次回购完成后30日内不得发行新股或出售、转让库藏股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B回购3.82万股，耗资约182.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120094471","title":"瑞博生物-B(06938)：10月22日回购3.72万股，涉资约174.27万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120094471","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120094471?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:42","pubTimestamp":1792665732,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年10月22日公告，公司当日在香港联交所场内回购H股3.72万股，约占回购前已发行股本169,582,710股的0.0219%。本次回购价格区间为每股46.52港元至47.20港元，合计涉资约174.27万港元。回购完成后，公司已发行股份数为169,545,510股，库藏股增至1,009,400股，总已发行股份数仍为170,554,910股。依照相关规定，回购后30日内，公司不得发行新股或处置库藏股。公司确认已遵守香港联交所相关上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B(06938)：10月22日回购3.72万股，涉资约174.27万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677673825","title":"瑞博生物-B(06938.HK)10月21日斥资1.05万港元回购200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677673825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677673825?lang=zh_cn&edition=full","pubTime":"2026-10-21 19:00","pubTimestamp":1792580453,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154708356","title":"瑞博生物-B：10月21日回购200股，耗资约1.05万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154708356","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154708356?lang=zh_cn&edition=full","pubTime":"2026-10-21 19:00","pubTimestamp":1792580451,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年10月21日公布翌日披露报表，披露当日通过香港联交所场内回购H股普通股200股，占公司已发行股本的约0.0001%。每股回购价格为52.25港元，总耗资约1.05万港元。根据公告，2026年6月5日公司获得了回购授权，可购回17,055,491股股份，截至目前已于包括本次在内的多次回购中合计购回972,200股，占授权通过日已发行股本的约0.57%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞博生物-B：10月21日回购200股，耗资约1.05万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676653250","title":"瑞博生物-B盘中涨超9% 拟收购Ribocure Pharmaceuticals AB剩余股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2676653250","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676653250?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:30","pubTimestamp":1792463400,"startTime":"0","endTime":"0","summary":"瑞博生物-B盘中涨超9%，截至发稿，股价上涨4.45%，现报52.85港元，成交额759.83万港元。目标公司Ribocure Pharmaceuticals AB为一家于2022年2月根据瑞典法律组织成立的临床阶段生物技术公司。目标公司目前拥有五个药物发现和临床前阶段项目，其中两项已经推进至接近临床申报阶段及两个主要对外授权合作项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvv6587001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.0363},{"period":"1month","weight":-0.224},{"period":"3month","weight":-0.1861},{"period":"6month","weight":-0.2806},{"period":"1year","weight":-0.2517},{"period":"ytd","weight":-0.2517}],"compareEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0735},{"period":"1year","weight":-0.0683},{"period":"ytd","weight":-0.0461}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}